China-Hospeq 2025 Unveils Major Breakthrough in Endovascular Robotic System
From August 15 to 17, 2025, the 31st China-Hospeq took place at the China National Convention Center in Beijing, bringing together international health authorities, hospital leaders, and industry experts to shape the future of global healthcare. At the Medical Innovation Pavilion, WeMed Medical unveiled its self-developed interventional robotics, demonstrating the power of Chinese intelligent manufacturing to drive innovation, foster international collaboration, and improve healthcare for people worldwide.
As a flagship industry event organized by the International Exchange and Cooperation Center of the National Health Commission, this year's expo carries special historical significance. Covering 22,000 square meters of exhibition space, it features more than 200 cutting-edge medical innovations from over 10 countries and regions-including China, Germany, the United States, the Netherlands, and Sweden. The exhibition highlights advances in medical imaging, surgical robotics, AI-driven healthcare models, and mobile diagnostics, collectively presenting products, technologies, and solutions designed to address the healthcare needs of China and its Belt and Road Initiative partner nations.
WeMed Medical's independently developed Endovascular Robotic System-featuring proprietary core algorithms, submillimeter precision, multimodal imaging integration, and AI technology-was the only Chinese brand selected for the Medical Innovation Pavilion. This recognition not only affirms WeMed Medical's technological strength at the national level but also highlights the rising presence of China's medical device industry on the global stage.
At the event, WeMed Medical unveiled its next-generation Endovascular Robotic System, highlighting innovation as the driving force behind its growth. The platform combines breakthrough technologies such as force feedback control, AI-powered navigation, biomimetic mechanisms, intelligent analytics, and smart workflow systems to enable precise treatment of vascular lesions. By supporting remote operation from outside the operating room, it not only minimizes radiation exposure for physicians but also enhances surgical efficiency and success.
This R&D approach-translating clinical needs into technological breakthroughs-demonstrates WeMed Medical's commitment to innovation-driven development. It is also the first Endovascular Robotic System in China to obtain Class III Medical Device approval through the NMPA's Green Channel for innovative devices. Backed by the National Key R&D Program and leading the development of national industry standards, this achievement marks a landmark milestone in China's rise as a global leader in high-end medical equipment.
Aligned with the vision of building a global community of shared future, WeMed Medical's strategic blueprint reflects a far-reaching international outlook. Through its dual-hub model in Beijing and Milan, the company has built a collaborative global network for R&D, manufacturing, and distribution of advanced medical technologies. Along the Belt and Road Initiative, WeMed Medical's clinical support services now reach more than 40 countries and regions worldwide.
